MedTrace Logo

Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer

NCT00553254 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2020-10-19

Study results available
· View outcomes & findings →

Summary

To assess the safety and efficacy of PF-00299804 in patients with advanced lung cancer.

Conditions

  • Carcinoma, Non Small Cell Lung

Interventions

DRUG

PF-00299804

Single arm (no comparator) study, oral once daily dosing, dose escalation (it is a phase 1/2 study) until disease progression, unacceptable toxicity or withdrawal of consent

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-05
Primary Completion
2010-08-03
Completion
2014-07-17

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00553254 on ClinicalTrials.gov